Standard BioTools Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Standard BioTools Inc. (LAB) had Lessee, Operating Lease, Liability, to be Paid, Year One of $8.42 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-03-16
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $8.42M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $9.72M.
- 2024-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $9.79M.
- 2024-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $9.70M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $8.42M 10-K · filed 2026-03-16 |
| 2024-12-31 | $9.72M 10-K · filed 2025-03-11 |
| 2024-09-30 | $9.79M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $9.70M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $9.69M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $8.09M 10-K · filed 2024-03-01 |
| 2022-12-31 | $7.80M 10-K · filed 2023-03-14 |
| 2021-12-31 | $7.48M 10-K · filed 2022-03-08 |
| 2020-12-31 | $7.57M 10-K · filed 2021-02-25 |
| 2020-09-30 | $7.36M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $7.28M 10-Q · filed 2020-08-07 |
| 2019-12-31 | $2.06M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |